These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12777990)

  • 21. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.
    Farshid G; Armes JE; Bell R; Cummings M; Fox S; Francis G; Haswell M; Morey A; McCue G; Raymond W; Robbins P; Bilous M
    Diagn Mol Pathol; 2010 Dec; 19(4):187-93. PubMed ID: 21052003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NIST physical standards for DNA-based medical testing.
    Barker PE; Watson MS; Ticehurst JR; Colbert JC; O'Connell CD
    J Clin Lab Anal; 2002; 16(1):5-10. PubMed ID: 11835524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
    Advani PP; Crozier JA; Perez EA
    Biomark Med; 2015; 9(1):35-49. PubMed ID: 25605454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASCO-CAP guidelines for breast predictive factor testing: an update.
    Hammond ME
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of the National Institute for Occupational Safety and Health-U.S. Environmental Protection Agency interlaboratory comparison of American National Standards Institute S12.6-1997 Methods A and B.
    Murphy WJ; Byrne DC; Gauger D; Ahroon WA; Berger E; Gerges SN; McKinley R; Witt B; Krieg EF
    J Acoust Soc Am; 2009 May; 125(5):3262-77. PubMed ID: 19425669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
    Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
    Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the selection and use of protocols for assignment of values to reference materials.
    Johnson AM; Sampson EJ; Blirup-Jensen S; Svendsen PJ
    Eur J Clin Chem Clin Biochem; 1996 Mar; 34(3):279-85. PubMed ID: 8721419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metrological requirements for clinical laboratory studies].
    Antonov VS
    Lab Delo; 1989; (8):67-71. PubMed ID: 2477637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lysozyme Reference Standard (Control 951) of the National Institute of Health Sciences].
    Kitajima A; Tagashira Y; Maekawa K; Tanimoto T; Okada S
    Eisei Shikenjo Hokoku; 1996; (114):128-9. PubMed ID: 9037882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
    J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamma-ray emitting test sources for Portal Monitors used for homeland security.
    Lucas L; Pibida L; Unterweger M; Karam L
    Radiat Prot Dosimetry; 2005; 113(1):108-11. PubMed ID: 15585520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.